|
1
|
Oakman C, Viale G and Di Leo A: Management
of triple negative breast cancer. Breast. 19:312–321. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carey LA, Dees EC, Sawyer L, Gatti L,
Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou
CM: The triple negative paradox: Primary tumor chemosensitivity of
breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Papa AL, Sidiqui A, Balasubramanian SU,
Sarangi S, Luchette M, Sengupta S and Harfouche R: PEGylated
liposomal Gemcitabine: Insights into a potential breast cancer
therapeutic. Cell Oncol (Dordr). 36:449–457. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ueno H, Kiyosawa K and Kaniwa N:
Pharmacogenomics of gemcitabine: Can genetic studies lead to
tailor-made therapy? Br J Cancer. 97:145–151. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Samanta D, Gilkes DM, Chaturvedi P, Xiang
L and Semenza GL: Hypoxia-inducible factors are required for
chemotherapy resistance of breast cancer stem cells. Proc Natl Acad
Sci USA. 111:E5429–E5438. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu B, Li J and Cairns MJ: Identifying
miRNAs, targets and functions. Brief Bioinform. 15:1–19. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang J, Yang M, Li Y and Han B: The role
of MicroRNAs in the chemoresistance of breast cancer. Drug Dev Res.
76:368–374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li HY, Liang JL, Kuo YL, Lee HH, Calkins
MJ, Chang HT, Lin FC, Chen YC, Hsu TI, Hsiao M, et al:
miR-105/93-3p promotes chemoresistance and circulating
miR-105/93-3p acts as a diagnostic biomarker for triple negative
breast cancer. Breast Cancer Res. 19:1332017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su
JL, Zhang MH and Liang HQ: MicroRNA-873 (miRNA-873) inhibits
glioblastoma tumorigenesis and metastasis by suppressing the
expression of IGF2BP1. J Biol Chem. 290:8938–8948. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cui J, Yang Y, Li H, Leng Y, Qian K, Huang
Q, Zhang C, Lu Z, Chen J, Sun T, et al: MiR-873 regulates ERα
transcriptional activity and tamoxifen resistance via targeting
CDK3 in breast cancer cells. Oncogene. 34:40182015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen X, Zhang Y, Shi Y, Lian H, Tu H, Han
S, Peng B, Liu W and He X: MiR-873 acts as a novel sensitizer of
glioma cells to cisplatin by targeting Bcl-2. Int J Oncol.
47:1603–1611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu DD, Li XS, Meng XN, Yan J and Zong ZH:
MicroRNA-873 mediates multidrug resistance in ovarian cancer cells
by targeting ABCB1. Tumour Biol. 37:10499–10506. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang P, Sun Y and Ma L: ZEB1: At the
crossroads of epithelial-mesenchymal transition, metastasis and
therapy resistance. Cell Cycle. 14:481–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Onder TT, Gupta PB, Mani SA, Yang J,
Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis
via multiple downstream transcriptional pathways. Cancer Res.
68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Karihtala P, Auvinen P, Kauppila S,
Haapasaari KM, Jukkola-Vuorinen A and Soini Y: Vimentin, zeb1 and
Sip1 are up-regulated in triple-negative and basal-like breast
cancers: Association with an aggressive tumour phenotype. Breast
Cancer Res Treat. 138:81–90. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Giordano A, Gao H, Anfossi S, Cohen E,
Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, et
al: Epithelial-mesenchymal transition and stem cell markers in
patients with HER2-positive metastatic breast cancer. Mol Cancer
Ther. 11:2526–2534. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lehmann W, Mossmann D, Kleemann J, Mock K,
Meisinger C, Brummer T, Herr R, Brabletz S, Stemmler MP and
Brabletz T: ZEB1 turns into a transcriptional activator by
interacting with YAP1 in aggressive cancer types. Nat Commun.
7:104982016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Davidson JD, Ma L, Flagella M, Geeganage
S, Gelbert LM and Slapak CA: An increase in the expression of
ribonucleotide reductase large subunit 1 is associated with
gemcitabine resistance in non-small cell lung cancer cell lines.
Cancer Res. 64:3761–3766. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sánchez-Tilló E, Lázaro A, Torrent R,
Cuatrecasas M, Vaquero EC, Castells A, Engel P and Postigo A: ZEB1
represses E-cadherin and induces an EMT by recruiting the SWI/SNF
chromatin-remodeling protein BRG1. Oncogene. 29:3490–3500. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Podo F, Buydens LM, Degani H, Hilhorst R,
Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J,
Monleon D, et al: Triple-negative breast cancer: Present challenges
and new perspectives. Mol Oncol. 4:209–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
O'Reilly EA, Gubbins L, Sharma S, Tully R,
Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell
M and McCann A: The fate of chemoresistance in triple negative
breast cancer (TNBC). BBA Clin. 3:257–275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang F, Zhang W, Shen Y and Guan X:
Identification of dysregulated microRNAs in triple-negative breast
cancer (review). Int J Oncol. 46:927–932. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu X, Tang H, Chen J, Song C, Yang L, Liu
P, Wang N and Xie X, Lin X and Xie X: MicroRNA-101 inhibits cell
progression and increases paclitaxel sensitivity by suppressing
MCL-1 expression in human triple-negative breast cancer.
Oncotarget. 6:20070–20083. 2015.PubMed/NCBI
|
|
27
|
Tan X, Peng J, Fu Y, An S, Rezaei K,
Tabbara S, Teal CB, Man YG, Brem RF and Fu SW: miR-638 mediated
regulation of BRCA1 affects DNA repair and sensitivity to UV and
cisplatin in triple-negative breast cancer. Breast Cancer Res.
16:4352014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aigner K, Dampier B, Descovich L, Mikula
M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist
P, et al: The transcription factor ZEB1 (deltaEF1) promotes tumour
cell dedifferentiation by repressing master regulators of
epithelial polarity. Oncogene. 26:6979–6988. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kahlert UD, Maciaczyk D, Doostkam S, Orr
BA, Simons B, Bogiel T, Reithmeier T, Prinz M, Schubert J,
Niedermann G, et al: Activation of canonical WNT/β-catenin
signaling enhances in vitro motility of glioblastoma cells by
activation of ZEB1 and other activators of
epithelial-to-mesenchymal transition. Cancer Lett. 325:42–53. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chua HL, Bhat-Nakshatri P, Clare SE,
Morimiya A, Badve S and Nakshatri H: NF-kappaB represses E-cadherin
expression and enhances epithelial to mesenchymal transition of
mammary epithelial cells: Potential involvement of ZEB-1 and ZEB-2.
Oncogene. 26:711–724. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peitzsch C, Kurth I, Kunz-Schughart L,
Baumann M and Dubrovska A: Discovery of the cancer stem cell
related determinants of radioresistance. Radiother Oncol.
108:378–387. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Allegra A, Alonci A, Penna G, Innao V,
Gerace D, Rotondo F and Musolino C: The cancer stem cell
hypothesis: A guide to potential molecular targets. Cancer Invest.
32:470–495. 2014. View Article : Google Scholar : PubMed/NCBI
|
